NYSEArca - Delayed Quote USD

First Trust Structured Credit Income Opportunities ETF (SCIO)

20.36

+0.00

+(0.02%)

At close: April 17 at 4:00:00 PM EDT

America's largest homebuilder warns of slow spring selling season as affordability, confidence weigh on buyers

America's largest homebuilder on Thursday detailed some of the big challenges facing the housing industry this spring selling season and over the balance of the year.

Yahoo Finance 2 days ago

DHI

LEN

LEN-B
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Enters into Agreement with Bradley L. Radoff and Michael TorokBOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the “Board”). Dr. Berman will serve as a non-voting observer to the Board through Atea’s 2025 Annual

GlobeNewswire 2 days ago

AVIR
-1.00%
COYA
Why 'beaten-up' sectors could lead the next market rebound

Uncertainty around President Trump's shifting tariff policy has investors wondering where to find stability and which sectors could see a strong rebound. Sound Income Strategies co-chief investment officer Eric Beyrich joins Catalysts to explain why he favors utilities (XLU) and staples (XLP) for stability. However, he notes that sectors that have been hit hard, such as materials (XLB) and energy (XLE), have strong potential of a big upside. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.

Yahoo Finance Video 4 days ago

XLU

XLP

XLE
Magnera to Report 2025 Second Quarter Results on May 7th

CHARLOTTE, N.C., April 14, 2025 (GLOBE NEWSWIRE) -- Magnera (NYSE: MAGN) expects to release its 2025 second quarter results prior to trading on the New York Stock Exchange on Wednesday, May 7, 2025. The earnings release, along with an investor presentation, will be available shortly thereafter on Magnera’s website at Investor Relations - Magnera. In conjunction with its release, Magnera’s Executive team will hold a conference call to discuss the 2025 second quarter financial results at 10:00am (

GlobeNewswire 5 days ago

MAGN
-3.58%
Oil prices may need to fall another 20% before a 'Trump put' stops this year's slide

Oil prices are forecast to continue falling in 2025, but the drop will need to be even more dramatic than expected for the Trump administration to step in and support markets.

Yahoo Finance 5 days ago

BZ=F

XLK

XLE
Dollar Hits 3-Year Low: Which ETFs Stand to Gain or Lose?

- The U.S. dollar fell to a three-year low Friday. - Gold ETFs have benefited from the lower dollar. - Currency ETFs are also reacting positively to the move.

etf.com 8 days ago

HEDJ

IAU

FXE
Veteran Energy Executive Gregory Goff Backs Elliott's Plan to Unlock Value at Phillips 66

Elliott Investment Management L.P. ("Elliott"), which manages funds that together are a top-five shareholder in Phillips 66 (NYSE: PSX) (the "Company" or "Phillips"), today issued the following statement about Gregory Goff's support for its "Streamline 66" campaign:

PR Newswire 10 days ago

XLE

PSX
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, Including up to 4 Million in US New Next-Generation HCV Therapies are Needed to Improve Patient Outcomes BOSTON, April 09, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical comp

GlobeNewswire 10 days ago

AVIR
-1.00%
Buying the dip: Focus on the 'what' & not the 'when'

Allspring Global Investments senior portfolio manager Bryant VanCronkhite sits with Brad Smith on Wealth to discuss how investors can navigate market uncertainty. The portfolio manager suggests focusing on moving capital into companies that will benefit from the eventual acceleration of the lower-end consumers, like those in the homebuilder (XHB) and healthcare (XLV) sectors. To watch more expert insights and analysis on the latest market action, check out more Wealth here.

Yahoo Finance Video 10 days ago

XHB

XLV
Lipella enrols all subjects in Phase IIa trial targeting oral lichen planus

The trial is designed to assess LP-310’s tolerability, preliminary efficacy, and safety in adults with symptomatic OLP.

Clinical Trials Arena 11 days ago

LIPO
+0.42%
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Topline Results Expected Q2 2025PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus (OLP). The Phase 2a trial has now fully enrolled parti

GlobeNewswire 11 days ago

LIPO
+0.42%
Oil Plunges To New Multi-Year Lows As Recession Fear Spikes

- Oil prices cratered on Friday, tumbling to their lowest levels since 2021. - WTI crude oil traded as low as $60.45 per barrel. - Energy remains one of the better-performing sectors this year.

etf.com 15 days ago

XLE

USO

SPY
Sector ETFs Offer Safe Haven as Tariff Woes Roil Markets

- Tech and consumer-discretionary sector ETFs fell more than 15% amid tariff announcements. - Defensive sectors like consumer staples, healthcare and utilities gained above 3%. - Performance divide shows investors seeking safe havens as trade policies evolve.

etf.com 15 days ago

XLC

XLRE

XLB
Sangoma to Present at the Planet MicroCap Showcase Las Vegas April 23-24, 2025

MARKHAM, Ontario, April 04, 2025--Sangoma Technologies Corporation (TSX: STC; Nasdaq: SANG) ("Sangoma" or the "Company"), uniquely offering businesses a choice of on-premises, cloud-based, or hybrid Communications as a Service solutions, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 8:00 AM PDT. Charles Salameh, Chief Executive Officer, will be hosting the presentation and answering question

Business Wire 15 days ago

SANG
-0.42%
FXU Assets Surge 29% With $426 Million Inflow

The First Trust Utilities AlphaDEX Fund (FXU) pulled in $425.7 million Monday. Here are the daily ETF fund flows for April 1, 2025.

etf.com 18 days ago

TLT

QLD

FXU
Commodities outperform in Q1 while US stocks slump

Stocks (^GSPC, ^IXIC, ^DJI) have underperformed so far in 2025, with all three major averages in the red on the last day of the first quarter. Yahoo Finance Senior Reporter Ines Ferré joins Morning Brief to explain how commodities and the energy sector have led market gains this year, emphasizing the surge in gold (GC=F) prices. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 19 days ago

^DJI

^IXIC

XLE
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

Episode titled "From Medicine to Biotech Innovation" now availablePITTSBURGH, March 31, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced that Co-Founder and Chief Medical Officer Dr. Michael Chancellor is featured in the latest episode of The Pharmaverse Podcast, hosted by pharmaceutical industry executive recruiter Micha

GlobeNewswire 19 days ago

LIPO
+0.42%
Sangoma Technologies Corporation (TSE:STC) is definitely on the radar of institutional investors who own 40% of the company

Key Insights Given the large stake in the stock by institutions, Sangoma Technologies' stock price might be vulnerable...

Simply Wall St. 22 days ago

SANG
-0.42%
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today issued the following statement: The Atea Board of Directors and management team have recently taken several decisive actions to enhance shareholder value, including: Launching a comprehensive review of strategic opportunities – In the fourth quart

GlobeNewswire 24 days ago

AVIR
-1.00%
Atea Shareholder Seeks Board Change, Plans to Nominate Directors at 2025 Annual Meeting

Atea Pharmaceuticals (AVIR) shareholder Radoff-JEC Group said in an open letter Wednesday that it pl

PREMIUM
MT Newswires 24 days ago

AVIR
-1.00%

Return	SCIO	Category
YTD	+2.78%	+1.82%
1-Year	+8.52%	+6.36%
3-Year	--	+3.20%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

First Trust Structured Credit Income Opportunities ETF (SCIO)

Related ETF News

America's largest homebuilder warns of slow spring selling season as affordability, confidence weigh on buyers

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Why 'beaten-up' sectors could lead the next market rebound

Magnera to Report 2025 Second Quarter Results on May 7th

Oil prices may need to fall another 20% before a 'Trump put' stops this year's slide

Dollar Hits 3-Year Low: Which ETFs Stand to Gain or Lose?

Veteran Energy Executive Gregory Goff Backs Elliott's Plan to Unlock Value at Phillips 66

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Buying the dip: Focus on the 'what' & not the 'when'

Lipella enrols all subjects in Phase IIa trial targeting oral lichen planus

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Oil Plunges To New Multi-Year Lows As Recession Fear Spikes

Sector ETFs Offer Safe Haven as Tariff Woes Roil Markets

Sangoma to Present at the Planet MicroCap Showcase Las Vegas April 23-24, 2025

FXU Assets Surge 29% With $426 Million Inflow

Commodities outperform in Q1 while US stocks slump

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

Sangoma Technologies Corporation (TSE:STC) is definitely on the radar of institutional investors who own 40% of the company

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

Atea Shareholder Seeks Board Change, Plans to Nominate Directors at 2025 Annual Meeting

Performance Overview